Clinical Trial Update: Single-dose of Nalmefene to Modulate Neural Alcohol Cue Reactivity [EARLY_Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating a single dose of nalmefene to modulate neural responses to alcohol cues has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Use Disorder

Drugs mentioned

• Nalmefene (nalmefene)

Snippet

Sponsor: Central Institute of Mental Health, Mannheim | Conditions: Alcoholism | EARLY_Phase 1 | Status: TERMINATED